Saturday, October 31, 2026

SNDL Stock Soars 31% In 21 Sessions: What's Driving The Surge?

ViaNews Editorial Team

September 27, 2023

SNDL Stock Soars 31% In 21 Sessions: What's Driving The Surge?

(VIANEWS) - Shares of SNDL Inc. (NASDAQ:SNDL) experienced an amazing 31.33% gain over 21 sessions, from EUR1.5 at 2023-08-28 to EUR1.97 as of 18:24 EST Wednesday evening. Despite this uptick, however, the stock is still 40.77% below its 52-week high of EUR3.36; currently however NASDAQ is up 0.22% at EUR13,092.855 following an earlier downward trend.

About SNDL Inc.

SNDL Inc. is a Canadian company that manufactures, distributes, and sells cannabis products for adult-use and medical markets. Operating through four segments - Liquor Retail, Cannabis Retail, Cannabis Operations and Investments - the company cultivates, distributes and sells these products under Top Leaf, Sundial Cannabis Palmetto Grasslands brands; wine beers spirits sold via wholly owned liquor stores while private sale of recreational cannabis sold from wholly owned as well as franchised retail cannabis stores; it was established back in 2006 under Sundial Growers Inc. with headquarters located in Calgary Canada - its original name being Sundial Growers Inc.

Yearly Analysis

SNDL Inc. is a Canadian cannabis company operating through its wholly owned subsidiary Sundial Growers Inc. Using this information as a base, here is my investment outlook: Yearly Top and Bottom Value SNDL Inc.'s stock is currently trading at EUR1.97, significantly below its 52-week high of EUR3.36 but higher than its 52-week low of EUR1.25, suggesting significant price movement over the past year. Anticipated Sales Growth SNDL Inc. is expected to achieve an outstanding sales growth rate of 1185% this year and 32.8 % next year, meaning its revenue should increase substantially and potentially lead to greater profitability in subsequent years. Earnings Before Interest, Taxes, Depreciation and Amortization mes SNDL Inc.'s EBITDA figure currently stands at 0.41; although not directly proportionate with revenue or expenses of the company, positive EBITDA indicates profits generated before factoring in interest expenses, taxes depreciation costs, amortization expenses etc. Overall, SNDL Inc. appears to be an attractive growth opportunity based on anticipated sales growth and positive EBITDA; however, investors should also take into consideration factors like financial health, competition and regulatory environment before making investment decisions.

Technical Analysis

SNDL Inc. (SNDL) has seen an increase in value over both its 50-day and 200-day moving averages of EUR1.49 and EUR1.83, respectively. Yet despite this promising development, its last reported volume (5245,052) is 22.32% lower than its average volume of 4,803,560. SNDL has experienced relatively stable performance over the past week, month and quarter with intraday variation averages of 1.71%, 1.45% and 4.19%, respectively. Its highest average volatility amplitude occurred within one week's time (4.52%) with one month having an amplitude of 4.411% before four quarters were over. Based on the stochastic oscillator - which measures overbought and oversold conditions - SNDL Inc. stock appears to be oversold (=20), suggesting it could be undervalued and set for a potential rebound. Overall, SNDL Inc. appears to be worth keeping an eye on; with its potential growth potential and oversold status providing investors an attractive investment opportunity.

Quarter Analysis

SNDL Inc. has experienced remarkable sales and revenue growth. Their 971.6% quarterly sales growth indicates an unprecedented surge in demand for their products or services; which could be attributable to various factors like effective marketing campaigns, new product releases or expanding market share. Remarkable is also the year-over-year quarterly revenue growth rate of 9.3% over the last twelve months, which shows how consistently increasing income can bring investors benefit. Investors should carefully assess a company's financial performance against industry benchmarks and competitors, and take an in-depth analysis of its financial statements and management strategy in order to gauge long-term growth potential and overall financial health.

Equity Analysis

According to available data, SNDL Inc. currently has an EPS of EUR-0.92, which indicates it is not currently profitable and should be of concern for investors, as it suggests there may not be enough revenue being generated to cover expenses. Return on Equity (ROE) for the twelve trailing months was negative -22.42%, suggesting that investors are not reaping profits from investments they've made into the company's shares. A negative ROE may signal to investors that management may not be properly using assets to generate profit and could indicate mismanagement by management. Overall, these financial metrics indicate that SNDL Inc. may not represent an attractive investment opportunity at this time. Investors may wish to conduct more in-depth investigation of its finances and business prospects before making any definitive investment decisions.

More news about SNDL Inc. (SNDL).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com